Edwards pegs growing TAVR sales to hospital hiring gains (fiercebiotech.com)
An update on Edward Life. I found the following bit interesting -
In TAVR, Edwards is pushing its new Resilia technology, which includes bovine pericardial tissue treated to make the replacement valve more resistant to calcification, where mineral deposits can grow to become a major cause of implant failure.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$6.15 |
Change
0.150(2.50%) |
Mkt cap ! $95.31M | |||
| Open | High | Low | Value | Volume |
| $6.00 | $6.15 | $6.00 | $41.13K | 6.816K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 165 | $6.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.20 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| AVR (ASX) Chart |